Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Flunisolide | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Flunisolide. |
| Betamethasone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Betamethasone. |
| Triamcinolone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Triamcinolone. |
| Prednisone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Prednisone. |
| Fludrocortisone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Fludrocortisone. |
| Hydrocortisone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Hydrocortisone. |
| Prednisolone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Prednisolone. |
| Methylprednisolone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Methylprednisolone. |
| Trilostane | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Trilostane. |
| Budesonide | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Budesonide. |
| Dexamethasone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Dexamethasone. |
| Corticotropin | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Corticotropin. |
| Cortisone acetate | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cortisone acetate. |
| Paramethasone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Paramethasone. |
| Aldosterone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Aldosterone. |
| Fluprednisolone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Fluprednisolone. |
| Meprednisone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Meprednisone. |
| Melengestrol | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Melengestrol. |
| Deflazacort | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Deflazacort. |
| Cortivazol | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cortivazol. |
| Prednylidene | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Prednylidene. |
| Cloprednol | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cloprednol. |
| Cortisone | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cortisone. |
| Etanercept | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Etanercept. |
| Peginterferon alfa-2a | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Peginterferon alfa-2a. |
| Interferon alfa-n1 | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-n1. |
| Interferon alfa-n3 | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-n3. |
| Peginterferon alfa-2b | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Peginterferon alfa-2b. |
| Anakinra | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Anakinra. |
| Interferon gamma-1b | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon gamma-1b. |
| Interferon alfa-2a | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-2a. |
| Aldesleukin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Rubella virus vaccine. |
| Gemtuzumab ozogamicin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemtuzumab ozogamicin. |
| Pegaspargase | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pegaspargase. |
| Infliximab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Infliximab. |
| Interferon beta-1b | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon beta-1b. |
| Interferon alfacon-1 | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfacon-1. |
| Trastuzumab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Trastuzumab. |
| Rituximab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Rituximab. |
| Basiliximab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Basiliximab. |
| Muromonab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Muromonab. |
| Ibritumomab tiuxetan | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab. |
| Cyclosporine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cyclosporine. |
| Alefacept | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept. |
| Efalizumab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-2b. |
| Natalizumab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Natalizumab. |
| Daclizumab | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Daclizumab. |
| Phenylalanine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Phenylalanine. |
| Bortezomib | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bortezomib. |
| Cladribine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cladribine. |
| Carmustine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Carmustine. |
| Amsacrine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Amsacrine. |
| Bleomycin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bleomycin. |
| Chlorambucil | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Raltitrexed. |
| Mitomycin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Mitomycin. |
| Bexarotene | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bexarotene. |
| Vindesine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Vindesine. |
| Floxuridine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Floxuridine. |
| Indomethacin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Indomethacin. |
| Tioguanine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Tioguanine. |
| Vinorelbine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Dexrazoxane. |
| Sorafenib | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Sorafenib. |
| Streptozocin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Streptozocin. |
| Trifluridine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Trifluridine. |
| Gemcitabine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemcitabine. |
| Teniposide | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Teniposide. |
| Epirubicin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Lenalidomide. |
| Altretamine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine. |
| Zidovudine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Zidovudine. |
| Cisplatin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Vincristine. |
| Fluorouracil | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pentostatin. |
| Methotrexate | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Methotrexate. |
| Carbamazepine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Carbamazepine. |
| Vinblastine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Vinblastine. |
| Linezolid | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Linezolid. |
| Imatinib | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Imatinib. |
| Clofarabine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Clofarabine. |
| Pemetrexed | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pemetrexed. |
| Mycophenolate mofetil | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Daunorubicin. |
| Irinotecan | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Irinotecan. |
| Methimazole | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Methimazole. |
| Etoposide | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Etoposide. |
| Sulfasalazine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Dacarbazine. |
| Temozolomide | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Temozolomide. |